CAMBRIDGE, Mass., Jan. 26, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, yesterday was named the recipient of the 2007 Corporate Vision Award by Gilda's Club New York City. The award recognizes an organization whose vision is to enhance and improve the lives of people living with cancer.
"Infinity is proud to be honored with the Corporate Vision Award from Gilda's Club, an organization that shares with Infinity a mission to better the lives of those affected by cancer," said Steven Holtzman, Chief Executive Officer of Infinity. "We are honored to receive this award in recognition of our team's commitment to discovering and developing novel therapies for cancer patients," added Julian Adams, Ph.D., President and Chief Scientific Officer of Infinity.
Named for Saturday Night Live comedienne Gilda Radner, Gilda's Club New York City opened in 1995 as a meeting place where men, women and children living with cancer -- as well as their families and friends -- can join with others to build emotional and social support as a supplement to medical care. Free of charge and nonprofit, Gilda's Club offers support and network groups, lectures, workshops and social events in a nonresidential, homelike setting.
Steven Holtzman and Julian Adams, Ph.D., accepted the Corporate Vision Award on behalf of Infinity at the Twelfth Annual Gilda's Club New York City Gala held at the Pierre Hotel, New York on Thursday, January 25, 2007. Infinity was honored for its dedication to creating novel therapeutics for the treatment of cancer and related conditions. Recently, Infinity announced positive interim data from its Phase I clinical trial with its lead anti-cancer agent, IPI-504. IPI-504 is currently being tested in patients with metastatic gastrointestinal stromal tumors and will shortly commence trials in patients with lung cancer. Infinity is also developing additional drug candidates that have the potential to address important unmet medical needs for the treatment of a broad range of cancers.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. For more information on Infinity, please refer to the company's website at http://www.ipi.com. INFI-G
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding future clinical trial activity for IPI-504 and the intended utilization and commercial potential of IPI-504. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical development phases, be approved for sale in any market or that, if approved, revenue from sales of such product will reach any specific level. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for any products it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included Infinity's quarterly report on Form 10-Q for the quarter ended September 30, 2006, as filed with the Securities and Exchange Commission on November 9, 2006. Further, any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.